Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLODRONATE DISODIUM

All products: Limited Use (codes 280, 358, 359)

Other products in the same Health Canada class (M05B, M05BA) — coverage varies; not interchangeable

  • Alendronate (Fosamax): general benefit, Not a benefit
  • Risedronate (Actonel DR): general benefit, Not a benefit
  • Etidronate (Didronel): limited Use 236, 237, Not a benefit
  • Zoledronic acid (Aclasta): limited Use 319, 436, 523, Not a benefit
  • Pamidronate (Aredia): not a benefit
  • Alendronate + cholecalciferol (Fosavance): general benefit

1 more in the class list below

Clasteon · DIN 02245828 · 400mg · capsule

Limited Use — Reason for Use code 280, 358, 359 requiredMarketed · checked 2026-09-02
StatusLimited Use — Reason for Use code 280, 358, 359 required
Write on scriptLU code 280, 358, 359 (patient must meet the criteria below)
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Ontario Limited Use criteria — code 280, 358, 359
Reason for Use code 280 For the control and prophylaxis of hypercalcemia of malignancy. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 358 For the treatment of bony metastases in patients with breast cancer. Coverage limit: LU Authorization Period: Indefinite Reason for Use code 359 For the prevention and treatment of osteolytic lesions in patients with multiple myeloma. Coverage limit: LU Authorization Period: Indefinite
1 brand, same coverage
Clasteon · DIN 02245828 Manufacturer: Knight Therapeutics Inc.; listing date 2004-10-14 Health Canada: Marketed since 2025-11-07 · brand CLASTEON · ATC M05BA02 CLODRONIC ACID · form Capsule · route Oral · ingredients CLODRONATE DISODIUM 400 MG · company Knight therapeutics inc. · schedule Prescription
Check this DIN again · Health Canada product record

Clasteon: Formulary list price $1.2083/unit (unit not stated in source; not the patient's cost)

Ministry pays: $1.2083 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69944 · Verify on the e-Formulary ↗ (DIN 02245828)

Source record
DIN 02245828: Clasteon Raw flags: chronicUseMed=Y, sec12=Y, sec3=Y Item: 920000212; group id 905; item number 2166; lccId 00124; manufacturer id KNT Source form: Cap; strength: 400mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below; chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $1.2083; ministry $1.2083 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02245828 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=69944
Interchangeable products
Ostac · DIN 01927078 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02245828
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, CLOPIDOGREL BISULFATE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

RISEDRONATE SODIUM

· 23 products · General benefit (20), Listed, not a benefit (3) · strengths: 35mg, 5mg, 30mg, 150mg · DR Tab, Tab

ETIDRONATE DISODIUM

· 2 products · Listed, not a benefit (1), Limited Use, codes 236, 237 (1) · strengths: 200mg · Tab

ZOLEDRONIC ACID

· 12 products · Limited Use, codes 319, 436, 523 (2), Off-Formulary Interchangeable, not an ODB benefit (10) · strengths: 5mg/100mL, 4mg/5mL · Inj Sol-100mL Pk (Preservative-Free), Inj Sol-5mL Pk (Preservative-Free)

PAMIDRONATE DISODIUM

· 9 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 3mg/mL, 6mg/mL, 9mg/mL · Inj Sol-10mL Vial

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

DENOSUMAB

· 8 products · Limited Use, codes 687, 688 (4), Limited Use, codes 686 (4) · strengths: 60mg/mL, 120mg/1.7mL · Inj Sol-1.0mL Pref Syr Pk (Preservative-Free), Inj Sol-Pref Syr, Inj Sol-Pref Syr (Preservative-Free), Inj Sol-Vial Pk, Inj Sol-Vial Pk (Preservative-Free)

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CLOPIDOGREL BISULFATE

· 19 products · General benefit (16), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 75mg, 300mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE CLASTEON (clodronate disodium) is indicated: • as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors. • for the management of hypercalcemia of malignancy. Prior to treatment with clodronate disodium, renal excretion of excess calcium should be promoted by restoration and maintenance of adequate fluid balance and urine output. In responsive patients, clodronate disodium inhibits osteoclastic activity and bone resorption by decreasing the flux of calcium from the bones and thus reducing the calcium level in the blood. https://pdf.hres.ca/dpd_pm/00082361.PDF PM date: not printed or not captured Source product: CLASTEON; DIN 02245828; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.